Budesonide-Formoterol Used As Needed Beneficial in Mild Asthma

Share this content:
Budesonide-Formoterol Used As Needed Beneficial in Mild Asthma
Budesonide-Formoterol Used As Needed Beneficial in Mild Asthma

THURSDAY, May 17, 2018 (HealthDay News) -- Inhaled combined budesonide-formoterol used as needed is beneficial for mild asthma, according to two studies published in the May 17 issue of the New England Journal of Medicine.

Paul M. O'Byrne, from McMaster University in Hamilton, Canada, and colleagues conducted a 52-week trial involving patients aged 12 years or older with mild asthma who were randomized to twice-daily placebo plus terbutaline used as needed (terbutaline, 1,277 patients), twice-daily placebo plus budesonide-formoterol used as needed (budesonide-formoterol, 1,277 patients), or twice-daily budesonide plus terbutaline used as needed (budesonide maintenance, 1,282 patients). The researchers found that budesonide-formoterol was superior to terbutaline (34.4 versus 31.1 percent of weeks; odds ratio, 1.14) with respect to the mean percentage of weeks with well-controlled asthma per patient and was inferior to budesonide maintenance therapy (34.4 versus 44.4 percent; odds ratio, 0.64).

Eric D. Bateman, M.D., from the University of Cape Town in South Africa, and colleagues randomized patients aged 12 years or older with mild asthma who were eligible for regular inhaled glucocorticoids to receive twice-daily placebo plus budesonide-formoterol used as needed (2,089 patients) or budesonide maintenance therapy plus terbutaline as needed (2,087 patients). The researchers found that budesonide-formoterol used as needed was non-inferior to budesonide maintenance for severe exacerbations, with annualized rates of severe exacerbations of 0.11 and 0.12, respectively (rate ratio, 0.97; upper one-sided 95 percent confidence limit, 1.16).

"These two trials show persuasively that treatment with budesonide-formoterol on an as-needed basis prevented the most serious outcomes of poorly controlled asthma," writes the author of an accompanying editorial.

AstraZeneca, which manufactures budesonide-formoterol, funded both studies.

Abstract/Full Text - O'Byrne (subscription or payment may be required)
Abstract/Full Text - Bateman (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Some California Mosquitoes Can Carry Zika Virus

Some California Mosquitoes Can Carry Zika Virus

Aedes aegypti mosquitoes found to transmit Zika virus

Periodontal Inflammation a Risk With Tongue Piercing

Periodontal Inflammation a Risk With Tongue Piercing

And, two young females with tongue piercings have deep lingual infrabony lesions, periodontitis

Risk of OD Highest for First Days of Opioid  Benzodiazepine Use

Risk of OD Highest for First Days of ...

Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use

is free, fast, and customized just for you!




Already a member?

Sign In Now »